These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 4826496)
1. Collection and presentation of combination data. Mancher RR Cancer Chemother Rep 2; 1974 Mar; 4(1):167-80. PubMed ID: 4826496 [No Abstract] [Full Text] [Related]
2. Clinical development of anticancer agents--a National Cancer Institute perspective. Marsoni S; Wittes R Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870 [No Abstract] [Full Text] [Related]
3. Planning combined therapy--the interaction of experimental and clinical studies. Carter SK Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498 [No Abstract] [Full Text] [Related]
4. [Introduction of new screening system in National Cancer Institute]. Tsukagoshi S Gan To Kagaku Ryoho; 1984 May; 11(5):1134-9. PubMed ID: 6539100 [No Abstract] [Full Text] [Related]
5. Screening of Philippine medicinal plants for anticancer agents using CCNSC Protocols. Masilungan VA; Vadlamudi S; Goldin A Cancer Chemother Rep 2; 1971 Apr; 2(1):135-40. PubMed ID: 5109412 [No Abstract] [Full Text] [Related]
7. Screening at the National Cancer Institute. Goldin A; Venditti JM; Carter SK Natl Cancer Inst Monogr; 1977 Mar; (45):37-48. PubMed ID: 337155 [No Abstract] [Full Text] [Related]
8. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435 [No Abstract] [Full Text] [Related]
9. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports. DeVita VT Cancer Treat Rep; 1984 Jan; 68(1):339-40. PubMed ID: 6692433 [No Abstract] [Full Text] [Related]
10. Origins and development of chemotherapy research at the National Cancer Institute. Zubrod CG Cancer Treat Rep; 1984 Jan; 68(1):9-19. PubMed ID: 6362871 [No Abstract] [Full Text] [Related]
11. Cancer problems lead list for potential medical marijuana research studies. Smigel K J Natl Cancer Inst; 1997 Sep; 89(17):1255. PubMed ID: 9293912 [No Abstract] [Full Text] [Related]
13. A review of the report of the 1966 Cancer Chemotherapy Collaborative Program Review Committee. Richardson AP Cancer Treat Rep; 1984 Jan; 68(1):340-1. PubMed ID: 6692434 [No Abstract] [Full Text] [Related]
14. Combination chemotherapy: considerations for design and analysis. Lloyd HH Cancer Chemother Rep 2; 1974 Mar; 4(1):157-65. PubMed ID: 4826495 [No Abstract] [Full Text] [Related]
15. The role of the National Cancer Institute in drug development. Doroshow J Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997 [No Abstract] [Full Text] [Related]
16. Preclinical toxicology protocols of the Laboratory of Toxicology. Prieur DJ; Young DM; Davis RD; Cooney DA; Guarino AM Natl Cancer Inst Monogr; 1977 Mar; (45):159-77. PubMed ID: 412104 [No Abstract] [Full Text] [Related]
17. Developing new agents for the treatment of childhood cancer. Kurmasheva R; Morton C; Houghton PJ Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407 [TBL] [Abstract][Full Text] [Related]
18. The preclinical new drug research program of the National Cancer Institute. Driscoll JS Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438 [TBL] [Abstract][Full Text] [Related]
19. Molecule of the month. Bortezomib. Drug News Perspect; 2003 Jun; 16(5):324. PubMed ID: 12942163 [No Abstract] [Full Text] [Related]
20. Scientists mine for genetic sources of cancer. Vickery K Provider; 2004 Feb; 30(2):20-3, 27-8, 33. PubMed ID: 14964916 [No Abstract] [Full Text] [Related] [Next] [New Search]